Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare but severe adverse event that can occur following Covid-19 vaccination, particularly with certain vaccines like AstraZeneca’s and its variant, Covishield. This syndrome involves an extreme immunological reaction that activates platelets and the coagulation system, leading to the formation of blood clots in veins and arteries. It can also result in a decrease in platelet count (thrombocytopenia). While initially associated with viral-vector-based vaccines, it has become evident that TTS can also occur with Covishield.
Symptoms of TTS can vary widely but often include persistent and worsening headaches, focal neurological symptoms like visual disturbances, clotting at unusual sites, and sometimes hemorrhage. These symptoms can manifest in various ways, including thrombosis in the lower extremities and lungs or at more unusual sites like blood vessels supplying the gut, brain, adrenal glands, and eyes.
“Patients may experience a broad spectrum of symptoms, ranging from severe headaches and particular neurological deficits to more subtle indications of thrombotic episodes. The co-occurrence of thrombosis and thrombocytopenia, however, is what sets TTS apart and emphasises the diagnostic conundrum that medical practitioners face. Differential diagnosis must account for a wide range of thrombotic and thrombocytopenic disorders. This necessitates a comprehensive evaluation and careful application of diagnostic modalities, including imaging tests, laboratory analyses, and haematological assessments,” she states.
Diagnosing TTS can be challenging and requires a high level of suspicion from healthcare providers. The co-occurrence of thrombosis and thrombocytopenia is a key diagnostic feature, but it must be differentiated from other thrombotic and thrombocytopenic disorders through comprehensive evaluation, including imaging tests, laboratory analyses, and hematological assessments.
Treatment of TTS involves balancing the risks of thrombosis and bleeding. Anticoagulation therapy may be necessary but must be tailored to each patient’s individual risk profile. Additional research is needed to understand the effects of adjuvant drugs such as intravenous immunoglobulins, platelet transfusions, and corticosteroids on the immune response associated with TTS. Interdisciplinary collaboration among cardiologists, hematologists, neurologists, and other specialists is crucial for developing a comprehensive treatment plan for TTS patients.
“When treating patients with TTS, cardiologists need to carefully consider the dangers of thrombosis and bleeding issues. In order to lessen the burden of thrombosis, anticoagulation is still necessary, but only after a thorough assessment of each patient’s particular risk profile and supporting documentation. To learn more about the effects of adjuvant drugs including intravenous immunoglobulins, platelet transfusion, and corticosteroids on the immune response connected to the pathophysiology of TTS, more research is required. The development of a cohesive treatment plan tailored to the requirements and clinical trajectory of TTS patients requires interdisciplinary collaboration between cardiologists, haematologists, neurologists, and other allied health specialists,” states Dr Arora.
Overall, TTS represents a significant challenge in the landscape of Covid-19 vaccination, highlighting the importance of vigilant monitoring and prompt recognition of symptoms to ensure timely intervention and management.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
